NASDAQ
CMMB

Chemomab Therapeutics Ltd DRC

Biotechnology
Healthcare

Prices are adjusted according to historical splits.

Chemomab Therapeutics Ltd DRC Stock Price

Vitals

Today's Low:
$1.02
Today's High:
$1.06
Open Price:
$1.02
52W Low:
$1.375
52W High:
$4.27
Prev. Close:
$1.06
Volume:
10273

Company Statistics

Market Cap.:
$19.12 million
Book Value:
3.278
Revenue TTM:
$0
Operating Margin TTM:
0%
Gross Profit TTM:
$0
Profit Margin:
0%
Return on Assets TTM:
-33.2%
Return on Equity TTM:
-56.6%

Company Profile

Chemomab Therapeutics Ltd DRC had its IPO on 2019-02-12 under the ticker symbol CMMB.

The company operates in the Healthcare sector and Biotechnology industry. Chemomab Therapeutics Ltd DRC has a staff strength of 0 employees.

Stock update

Shares of Chemomab Therapeutics Ltd DRC opened at $1.02 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $1.02 - $1.06, and closed at $1.05.

This is a -0.94% slip from the previous day's closing price.

A total volume of 10,273 shares were traded at the close of the day’s session.

In the last one week, shares of Chemomab Therapeutics Ltd DRC have slipped by -7.89%.

Chemomab Therapeutics Ltd DRC's Key Ratios

Chemomab Therapeutics Ltd DRC has a market cap of $19.12 million, indicating a price to book ratio of 0.6199 and a price to sales ratio of 0.

In the last 12-months Chemomab Therapeutics Ltd DRC’s revenue was $0 with a gross profit of $0 and an EBITDA of $-28475000. The EBITDA ratio measures Chemomab Therapeutics Ltd DRC's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Chemomab Therapeutics Ltd DRC’s operating margin was 0% while its return on assets stood at -33.2% with a return of equity of -56.6%.

In Q1, Chemomab Therapeutics Ltd DRC’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

Chemomab Therapeutics Ltd DRC’s PE and PEG Ratio

Forward PE
13.0039
Trailing PE
0
PEG

Its diluted EPS in the last 12-months stands at $-3.06 per share while it has a forward price to earnings multiple of 13.0039 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Chemomab Therapeutics Ltd DRC’s profitability.

Chemomab Therapeutics Ltd DRC stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of 0.7466. Its price to sales ratio in the trailing 12-months stood at 0.

Chemomab Therapeutics Ltd DRC stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$35.01 million
Total Liabilities
$7.00 million
Operating Cash Flow
$0
Capital Expenditure
$1000
Dividend Payout Ratio
0%

Chemomab Therapeutics Ltd DRC ended 2024 with $35.01 million in total assets and $0 in total liabilities. Its intangible assets were valued at $35.01 million while shareholder equity stood at $27.95 million.

Chemomab Therapeutics Ltd DRC ended 2024 with $0 in deferred long-term liabilities, $7.00 million in other current liabilities, -1218000.00 in common stock, $-72572000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $20.77 million and cash and short-term investments were $32.71 million. The company’s total short-term debt was $115,000 while long-term debt stood at $0.

Chemomab Therapeutics Ltd DRC’s total current assets stands at $33.78 million while long-term investments were $0 and short-term investments were $11.94 million. Its net receivables were $995000.00 compared to accounts payable of $2.22 million and inventory worth $0.

In 2024, Chemomab Therapeutics Ltd DRC's operating cash flow was $0 while its capital expenditure stood at $1000.

Comparatively, Chemomab Therapeutics Ltd DRC paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$1.05
52-Week High
$4.27
52-Week Low
$1.375
Analyst Target Price
$14.67

Chemomab Therapeutics Ltd DRC stock is currently trading at $1.05 per share. It touched a 52-week high of $4.27 and a 52-week low of $4.27. Analysts tracking the stock have a 12-month average target price of $14.67.

Its 50-day moving average was $1.22 and 200-day moving average was $1.69 The short ratio stood at 21.56 indicating a short percent outstanding of 0%.

Around 2144% of the company’s stock are held by insiders while 3357.8% are held by institutions.

Frequently Asked Questions About Chemomab Therapeutics Ltd DRC

The stock symbol (also called stock or share ticker) of Chemomab Therapeutics Ltd DRC is CMMB

The IPO of Chemomab Therapeutics Ltd DRC took place on 2019-02-12

Similar Industry Stocks (Biotechnology)

Last Price
Chg
Chg%
$12.75
-0.01
-0.08%
$13.56
0.01
+0.07%
$40.32
-1.24
-2.98%
$2.85
0.05
+1.79%
GEE LTD. (GEE)
$87.3
5.64
+6.91%
$29.7
-0.6
-1.98%
$331.75
-23.2
-6.54%
$26.6
0.18
+0.68%
$58.1
-0.65
-1.11%
$9.85
0.14
+1.44%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company’s lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.

Address

Building 7, Tel Aviv, Israel, 6158002